{
    "nct_id": "NCT06377696",
    "official_title": "Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients with History of Cranial Radiation",
    "inclusion_criteria": "* Age ≥ 18 years\n* Diagnosis of brain tumor requiring cranial radiation treatment NOTE: Patient may be enrolled during or up to 5 years after completion of cranial radiation administered for treatment of primary or metastatic intracranial tumor\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 70\n* Expected survival ≥ 6 months in the opinion of treatment team\n* Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations\n* The following laboratory values obtained ≤ 30 days prior to registration:\n\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN [≤ 5 x upper limit normal (ULN) for patients with baseline liver disease]\n* Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only\n* Ability to complete cognitive assessments and questionnaires by themselves or with assistance\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings\n* Pregnant or nursing, imprisoned, or lacking capacity for understanding\n* Unable to swallow tablets or at risk for impaired absorption of oral medication\n* Currently taking the study agent (i.e., metformin), and cannot safely discontinue if randomized to the control group (Group B)\n* Known hypersensitivity or allergy to metformin\n* Current use of resveratrol, CoQ10 (coenzyme Q10), coconut oil/other medium chain triglyceride-containing (e.g., Axona) supplements, or curcumin and unwilling to discontinue prior to registration and remain off these agents for study duration\n* Unable to read and speak English. Note: English doses not to need to be primary language",
    "miscellaneous_criteria": ""
}